Global Biologics Contract Development & Manufacturing Organization (CDMO) Market—Companies-to-Action

Global Biologics Contract Development & Manufacturing Organization (CDMO) Market—Companies-to-Action

Establishment of Need-based Business Models with Advancements in Manufacturing Techniques is Driving Market Growth

RELEASE DATE
12-Apr-2018
REGION
Europe
Research Code: MD88-01-00-00-00
SKU: HC02993-EU-MR_21771
$3,000.00
In stock
SKU
HC02993-EU-MR_21771
$3,000.00
Links

Pay by invoice

ENQUIRE NOW

Description

The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies toward biologics development and manufacturing, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products.

The biologics manufacturing industry is presently in a growth stage owing to factors such as complexity of molecules and complex manufacturing processes. This presents an immense potential for the market with pharmaceutical MNCs looking for outsourcing partners providing them with biologics development and manufacturing services at comparatively lower costs. The advent of personalized medicine calls for a shift toward flexible, small-volume manufacturing using single-use/ disposable bioreactors and using bio-analytical capabilities, thus exploring continuous processing technologies in modular facilities. Presently, the outsourcing of bio-analytical activities is comparatively lower across the industry, which provides ample opportunities to outsourcing partners in terms of services such as bio-analytical testing by means of building entrenched relationships with pharma MNCs. Further, bio-CDMOs are making use of advanced continuous manufacturing processes as opposed to the traditional batch processes, which increases the time-to-market of the biologics and help the firms meet the growing demand. CDMOs are adopting several newer business models such as risk sharing models and value-based models to achieve a competitive edge in the ever-changing biologics manufacturing landscape. Using these approaches, there are also able to meet specific needs of their pharma partners in terms of drug development through out-licensing of the development and manufacturing expenses and acquiring flexible and modular manufacturing capabilities, thereby meeting the demand.

In addition to the above-mentioned strategic analysis, this report also provides information on some of the recent collaborations of the bio-CDMOs.

Key Issues Addressed

  • What are the current growth opportunities in the bio-CDMO market? What are some of the external factors that affect this market?
  • Which are the key bio-CDMOs that are introducing unique and innovative solutions in the market? How do these solutions transform the market?
  • How will the bio-CDMO market transform the industry paradigms in the next five years?
  • What are the strategic imperatives to be adopted by the bio-CDMOs to bring about this market transformation?
  • What is the growth potential of this rapidly expanding Bio-CDMO market?
  • Which CDMO business model is best suited to meet the growing outsourcing needs of the biopharmaceutical industry?

Table of Contents

Methodology

Key Findings—Analysis of Companies-to-Action

Scope and Segmentation

Companies-to-Action Value Creators

Opportunities and Threats

Leading Bio-CDMOs to Watch

Business Overview

Company’s Value Propositions

Major Partnerships and Agreements

Revenue and Growth Plans

Business Overview

Company’s Value Propositions

Major Partnerships and Agreements

Revenue and Growth Plans

Business Overview

Company’s Value Propositions

Major Partnerships and Agreements

Revenue and Growth Plans

Business Overview

Company’s Value Propositions

Major Partnerships and Agreements

Revenue and Growth Plans

Business Overview

Company’s Value Propositions

Major Partnerships and Agreements

Revenue and Growth Plans

Business Overview

Company’s Value Propositions

Major Partnerships and Agreements

Revenue and Growth Plans

Business Overview

Company’s Value Propositions

Major Partnerships and Agreements

Revenue and Growth Plans

Business Models in Bio-CDMO Market

Company Snapshot—Bio-CDMOs

Competitive Playbook—Market Share Analysis

Case Study—Thermo Fisher: Patheon

Key Mergers, Acquisitions and Partnership Agreements

Key Investments and Facility Expansions

Transformation in Industry Eco-system

5 Major Growth Opportunities

Strategic Imperatives for Success and Growth

Conclusion—Key Takeaways

Legal Disclaimer

Key Mergers, Acquisitions and Partnership Agreements

Key Investments and Facility Expansions

List of Vendors

List of Exhibits

List of Figures
  • 1. Total Bio-CDMO Market: Company Snapshot—Bio-CDMOs, Global, 2017
  • 2. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2016–2017
  • 3. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2016–2018
  • 4. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2016
  • 5. Bio-CDMO Market: Facility Expansions and Investments, Global, 2013–2018
  • 6. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2015–2016
  • 7. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2014
  • 8. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2012–2014
  • 9. Bio-CDMO Market: Key Investments and Facility Expansions, Global, 2014–2015
List of Charts
  • 1. Bio-CDMO Market: C2A Value Creators, Global, 2017
  • 2. Bio-CDMO Market: Lonza Revenue Percentage Breakdown by Services Offerings, Global, 2017
  • 3. Bio-CDMO Market: Lonza Overall Sales, Global, 2012–2017
  • 4. Bio-CDMO Market: BI BioXcellence Contract Revenue, Global, 2012–2017
  • 5. Bio-CDMO Market: Patheon Revenue Percentage Breakdown by Services Offerings, Global, 2016
  • 6. Bio-CDMO Market: Patheon Contract Revenue, Global, 2012–2017
  • 7. Bio-CDMO Market: Samsung BioLogics Contract Revenue, Global, 2015–2017
  • 8. Bio-CDMO Market: Catalent Contract Revenue, Global, 2012–2017
  • 9. Bio-CDMO Market: Wuxi Biologics Percentage Breakdown for Services Offerings, Global, 2016
  • 10. Bio-CDMO Market: Business Models, Global, 2017
  • 11. Bio-CDMO Market: Market Share Analysis, Global, 2017
  • 12. Bio-CDMO Market: Major Growth Opportunities, Global, 2017
Related Research

Growth Insights—Real World Evidence Analytics Solutions Market

Release Date: 24-Apr-18
Region: North America

Global Biologics Market—Companies-to-Action

Release Date: 20-Nov-17
Region: North America

East African Pharmaceutical Market, Forecast to 2021

Release Date: 27-Sep-17
Region: Africa

Global CRO Market, Forecast to 2021

Release Date: 19-Apr-17
Region: Asia Pacific

Biomarkers Enabling Diabetes and Obesity Management

Release Date: 02-Mar-17
Region: Global

2016 Indonesia Transformational Health Insights

Release Date: 31-May-2016
Region: Asia Pacific

Pharmaceutical Market Access Strategy for Ethiopia

Release Date: 27-May-2016
Region: Africa

Vital Signs The Analyst's Perspective - April 2016 Issue

Release Date: 24-May-2016
Region: Global
The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies toward biologics development and manufacturing, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. The biologics manufacturing industry is presently in a growth stage owing to factors such as complexity of molecules and complex manufacturing processes. This presents an immense potential for the market with pharmaceutical MNCs looking for outsourcing partners providing them with biologics development and manufacturing services at comparatively lower costs. The advent of personalized medicine calls for a shift toward flexible, small-volume manufacturing using single-use/ disposable bioreactors and using bio-analytical capabilities, thus exploring continuous processing technologies in modular facilities. Presently, the outsourcing of bio-analytical activities is comparatively lower across the industry, which provides ample opportunities to outsourcing partners in terms of services such as bio-analytical testing by means of building entrenched relationships with pharma MNCs. Further, bio-CDMOs are making use of advanced continuous manufacturing processes as opposed to the traditional batch processes, which increases the time-to-market of the biologics and help the firms meet the growing demand. CDMOs are adopting several newer business models such as risk sharing models and value-based models to achieve a competitive edge in the ever-changing biologics manufacturing landscape. Using these approaches, there are also able to meet specific needs of their pharma partners in terms of drug development through out-licensing of the development and
More Information
No Index No
Podcast No
Table of Contents || Methodology~ | Executive Summary~ || Key Findings—Analysis of Companies-to-Action~ || Scope and Segmentation~ | Companies-to-Action Overview~ || Companies-to-Action Value Creators~ || Opportunities and Threats~ || Leading Bio-CDMOs to Watch~ | Companies-to-Action Profiles—Lonza~ || Business Overview~ || Company’s Value Propositions~ || Major Partnerships and Agreements~ || Revenue and Growth Plans~ | Companies-to-Action Profiles—Boehringer Ingelheim BioXcellence™~ || Business Overview~ || Company’s Value Propositions~ || Major Partnerships and Agreements~ || Revenue and Growth Plans~ | Companies-to-Action Profiles—Patheon (Acquired by Thermo Fisher Scientific)~ || Business Overview~ || Company’s Value Propositions~ || Major Partnerships and Agreements~ || Revenue and Growth Plans~ | Companies-to-Watch Profiles—Samsung BioLogics~ || Business Overview~ || Company’s Value Propositions~ || Major Partnerships and Agreements~ || Revenue and Growth Plans~ | Companies-to-Action Profiles—Catalent~ || Business Overview~ || Company’s Value Propositions~ || Major Partnerships and Agreements~ || Revenue and Growth Plans~ | Companies-to-Watch Profiles—Wuxi Biologics~ || Business Overview~ || Company’s Value Propositions~ || Major Partnerships and Agreements~ || Revenue and Growth Plans~ | Companies-to-Action Profiles—AGC Biologics (Previously CMC Biologics)~ || Business Overview~ || Company’s Value Propositions~ || Major Partnerships and Agreements~ || Revenue and Growth Plans~ | Growth Environment—Business Models and Competitive Playbook~ || Business Models in Bio-CDMO Market~ || Company Snapshot—Bio-CDMOs~ || Competitive Playbook—Market Share Analysis~ || Case Study—Thermo Fisher: Patheon~ || Key Mergers, Acquisitions and Partnership Agreements~ || Key Investments and Facility Expansions~ | Growth Environment and Companies to Action~ || Transformation in Industry Eco-system~ || 5 Major Growth Opportunities~ || Strategic Imperatives for Success and Growth~ | The Last Word~ || Conclusion—Key Takeaways~ || Legal Disclaimer~ | Appendix~ || Key Mergers, Acquisitions and Partnership Agreements~ || Key Investments and Facility Expansions~ || List of Vendors~ || List of Exhibits~ | The Frost & Sullivan Story~
List of Charts and Figures 1. Total Bio-CDMO Market: Company Snapshot—Bio-CDMOs, Global, 2017~ 2. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2016–2017~ 3. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2016–2018~ 4. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2016~ 5. Bio-CDMO Market: Facility Expansions and Investments, Global, 2013–2018~ 6. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2015–2016~ 7. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2014~ 8. Bio-CDMO Market: Key Mergers and Acquisitions, Global, 2012–2014~ 9. Bio-CDMO Market: Key Investments and Facility Expansions, Global, 2014–2015~| 1. Bio-CDMO Market: C2A Value Creators, Global, 2017~ 2. Bio-CDMO Market: Lonza Revenue Percentage Breakdown by Services Offerings, Global, 2017~ 3. Bio-CDMO Market: Lonza Overall Sales, Global, 2012–2017~ 4. Bio-CDMO Market: BI BioXcellence Contract Revenue, Global, 2012–2017~ 5. Bio-CDMO Market: Patheon Revenue Percentage Breakdown by Services Offerings, Global, 2016~ 6. Bio-CDMO Market: Patheon Contract Revenue, Global, 2012–2017~ 7. Bio-CDMO Market: Samsung BioLogics Contract Revenue, Global, 2015–2017~ 8. Bio-CDMO Market: Catalent Contract Revenue, Global, 2012–2017~ 9. Bio-CDMO Market: Wuxi Biologics Percentage Breakdown for Services Offerings, Global, 2016~ 10. Bio-CDMO Market: Business Models, Global, 2017~ 11. Bio-CDMO Market: Market Share Analysis, Global, 2017~ 12. Bio-CDMO Market: Major Growth Opportunities, Global, 2017~
Lightbox Content World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019
Author Unmesh Lal
Industries Healthcare
WIP Number MD88-01-00-00-00
Keyword 1 CMDO
Is Prebook No
GPS Codes 9571-B1,9600-B1,9611-B1,9A42-B1,9A43-B1